Recent advances in the generation of human monoclonal antibody

Makiko Yamashita, Yoshinori Katakura, Sanetaka Shirshata

Research output: Contribution to journalArticle

Abstract

The use of monoclonal antibodies (mAbs) has now gained a niche as an epochal breakthrough in medicine. Engineered antibodies (Abs) currently account for over 30% of biopharmaceuticals in clinical trials. Several methods to generate human mAbs have evolved, such as (1) immortalization of antigen-specific human B cell hybridoma technology, (2) generation of chimeric and humanized antibody (Ab) from mouse Ab by genetic engineering, (3) acquisition of antigen-specific human B cells by the phage display method, and (4) development of transgenic mice for producing human mAbs. Besides these technologies, we have independently developed a method to generate human mAbs by combining the method of in vitro immunization using peripheral blood mononuclear cells and the phage display method. In this paper, we review the developments in these technologies for generating human mAbs.
Original languageEnglish
Pages (from-to)55-60
Number of pages6
JournalCytotechnology
Volume55
Issue number2-3
DOIs
Publication statusPublished - 2007

Fingerprint

Monoclonal antibodies
Monoclonal Antibodies
Antibodies
Bacteriophages
Antigens
Technology
Display devices
Cells
Immunization
B-Lymphocytes
Antibodies, Monoclonal, Humanized
Genetic engineering
Genetic Engineering
Hybridomas
Medicine
Blood
Transgenic Mice
Blood Cells
Clinical Trials

Cite this

Recent advances in the generation of human monoclonal antibody. / Yamashita, Makiko; Katakura, Yoshinori; Shirshata, Sanetaka.

In: Cytotechnology, Vol. 55, No. 2-3, 2007, p. 55-60.

Research output: Contribution to journalArticle

Yamashita, Makiko ; Katakura, Yoshinori ; Shirshata, Sanetaka. / Recent advances in the generation of human monoclonal antibody. In: Cytotechnology. 2007 ; Vol. 55, No. 2-3. pp. 55-60.
@article{adef55f751814f2ba1df0ce3a2eeb7af,
title = "Recent advances in the generation of human monoclonal antibody",
abstract = "The use of monoclonal antibodies (mAbs) has now gained a niche as an epochal breakthrough in medicine. Engineered antibodies (Abs) currently account for over 30{\%} of biopharmaceuticals in clinical trials. Several methods to generate human mAbs have evolved, such as (1) immortalization of antigen-specific human B cell hybridoma technology, (2) generation of chimeric and humanized antibody (Ab) from mouse Ab by genetic engineering, (3) acquisition of antigen-specific human B cells by the phage display method, and (4) development of transgenic mice for producing human mAbs. Besides these technologies, we have independently developed a method to generate human mAbs by combining the method of in vitro immunization using peripheral blood mononuclear cells and the phage display method. In this paper, we review the developments in these technologies for generating human mAbs.",
author = "Makiko Yamashita and Yoshinori Katakura and Sanetaka Shirshata",
year = "2007",
doi = "10.1007/s10616-007-9072-5",
language = "English",
volume = "55",
pages = "55--60",
journal = "Cytotechnology",
issn = "0920-9069",
publisher = "Springer Netherlands",
number = "2-3",

}

TY - JOUR

T1 - Recent advances in the generation of human monoclonal antibody

AU - Yamashita, Makiko

AU - Katakura, Yoshinori

AU - Shirshata, Sanetaka

PY - 2007

Y1 - 2007

N2 - The use of monoclonal antibodies (mAbs) has now gained a niche as an epochal breakthrough in medicine. Engineered antibodies (Abs) currently account for over 30% of biopharmaceuticals in clinical trials. Several methods to generate human mAbs have evolved, such as (1) immortalization of antigen-specific human B cell hybridoma technology, (2) generation of chimeric and humanized antibody (Ab) from mouse Ab by genetic engineering, (3) acquisition of antigen-specific human B cells by the phage display method, and (4) development of transgenic mice for producing human mAbs. Besides these technologies, we have independently developed a method to generate human mAbs by combining the method of in vitro immunization using peripheral blood mononuclear cells and the phage display method. In this paper, we review the developments in these technologies for generating human mAbs.

AB - The use of monoclonal antibodies (mAbs) has now gained a niche as an epochal breakthrough in medicine. Engineered antibodies (Abs) currently account for over 30% of biopharmaceuticals in clinical trials. Several methods to generate human mAbs have evolved, such as (1) immortalization of antigen-specific human B cell hybridoma technology, (2) generation of chimeric and humanized antibody (Ab) from mouse Ab by genetic engineering, (3) acquisition of antigen-specific human B cells by the phage display method, and (4) development of transgenic mice for producing human mAbs. Besides these technologies, we have independently developed a method to generate human mAbs by combining the method of in vitro immunization using peripheral blood mononuclear cells and the phage display method. In this paper, we review the developments in these technologies for generating human mAbs.

U2 - 10.1007/s10616-007-9072-5

DO - 10.1007/s10616-007-9072-5

M3 - Article

VL - 55

SP - 55

EP - 60

JO - Cytotechnology

JF - Cytotechnology

SN - 0920-9069

IS - 2-3

ER -